1. van der Heijde, D, Ramiro, S, Landewe, R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978–991.
Google Scholar | Crossref | Medline | ISI2. Braun, J, Inman, R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. Ann Rheum Dis 2010; 69: 1264–1268.
Google Scholar | Crossref | Medline3. Michelena, X, López-Medina, C, Marzo-Ortega, H. Non-radiographic versus radiographic axSpA: what’s in a name? Rheumatology 2020; 59: iv18–iv24.
Google Scholar | Crossref | Medline4. Baraliakos, X, Sewerin, P, de Miguel, E, et al. Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial. BMC Musculoskelet Disord 2020; 21: 767.
Google Scholar | Crossref | Medline5. Redeker, I, Siegmund, B, Ghoreschi, K, et al. The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20972610.
Google Scholar | SAGE Journals6. Moltó, A, Etcheto, A, van der Heijde, D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016; 75: 1016–1023.
Google Scholar | Crossref | Medline7. Boel, A, Molto, A, van der Heijde, D, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis 2019; 78: 1545–1549.
Google Scholar | Crossref | Medline8. Lopez-Medina, C, Ramiro, S, van der Heijde, D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open 2019; 5: e001108.
Google Scholar | Crossref | Medline9. Kiltz, U, Baraliakos, X, Karakostas, P, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res 2012; 64: 1415–1422.
Google Scholar | Crossref | Medline | ISI10. Kiltz, U, van der Heijde, D, Boonen, A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 2018; 77: 1311–1317.
Google Scholar | Crossref | Medline11. Kiltz, U, van der Heijde, D, Boonen, A, et al. The ASAS Health Index (ASAS HI) – a new tool to assess the health status of patients with spondyloarthritis. Clin Exp Rheumatol 2014; 32(5, Suppl. 85): S105–S108.
Google Scholar12. Kiltz, U, Essers, I, Hiligsmann, M, et al. Which aspects of health are most important for patients with spondyloarthritis? A best worst scaling based on the ASAS Health Index. Rheumatology 2016; 55: 1771–1776.
Google Scholar | Crossref | Medline13. Packham, J. Optimizing outcomes for ankylosing spondylitis and axial spondyloarthritis patients: a holistic approach to care. Rheumatology 2018; 57: vi29–vi34.
Google Scholar | Crossref14. Smolen, JS, Schols, M, Braun, J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018; 77: 3–17.
Google Scholar | Crossref | Medline15. Ward, MM, Deodhar, A, Gensler, LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2019; 71: 1599–1613.
Google Scholar | Crossref | Medline16. Noureldin, B, Barkham, N. The current standard of care and the unmet needs for axial spondyloarthritis. Rheumatology 2018; 57: vi10–vi17.
Google Scholar | Crossref | Medline17. Coates, LC, Marzo-Ortega, H, Bennett, AN, et al. Anti-TNF therapy in ankylosing spondylitis: insights for the clinician. Ther Adv Musculoskelet Dis 2010; 2: 37–43.
Google Scholar | SAGE Journals18. So, A, Inman, RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol 2018; 32: 453–471.
Google Scholar | Crossref | Medline19. Furst, DE, Louie, JS. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther 2019; 21: 135.
Google Scholar | Crossref | Medline20. McGonagle, DG, McInnes, IB, Kirkham, BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 2019; 78: 1167–1178.
Google Scholar | Crossref | Medline21. Miossec, P, Kolls, JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11: 763–776.
Google Scholar | Crossref | Medline | ISI22. Brembilla, NC, Senra, L, Boehncke, WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 2018; 9: 1682.
Google Scholar | Crossref | Medline23. Baeten, D, Sieper, J, Braun, J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373: 2534–2548.
Google Scholar | Crossref | Medline | ISI24. San Koo, B, Kim, TH. The role of ixekizumab in non-radiographic axial spondyloarthritis. Ther Adv Musculoskelet Dis 2021; 13: 1759720X20986734.
Google Scholar | SAGE Journals25. Wei, JC, Kim, TH, Kishimoto, M, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis 2021; 80: 1014–1021.
Google Scholar | Crossref26. van der Heijde, D, Gensler, LS, Deodhar, A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis 2020; 79: 595–604.
Google Scholar | Crossref | Medline27. European Medicines Agency (EMA) . COSENTYX® (secukinumab). Summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf (2021, accessed 9 July 2021).
Google Scholar28. Braun, J, Baraliakos, X, Kiltz, U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2016; 16: 711–722.
Google Scholar | Crossref | Medline29. US Food & Drug Administration (FDA) . COSENTYX® (secukinumab). Highlights of prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125504s035lbl.pdf (2021, accessed 9 July 2021).
Google Scholar30. Pavelka, K, Kivitz, A, Dokoupilova, E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017; 19: 285.
Google Scholar | Crossref | Medline31. Kivitz, AJ, Wagner, U, Dokoupilova, E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther 2018; 5: 447–462.
Google Scholar | Crossref | Medline32. Huang, F, Sun, F, Wan, WG, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. Chin Med J 2020; 133: 2521–2531.
Google Scholar | Crossref | Medline33. Deodhar, A, Blanco, R, Dokoupilova, E, et al. Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study. Arthritis Rheumatol 2021; 73: 110–120.
Google Scholar | Crossref | Medline34. Rudwaleit, M, Landewe, R, van der Heijde, D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770–776.
Google Scholar | Crossref | Medline | ISI35. Landewe, R, van Tubergen, A. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep 2015; 17: 47.
Google Scholar | Crossref | Medline36. Marzo-Ortega, H, Sieper, J, Kivitz, AJ, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol 2020; 2: e339–e346.
Google Scholar | Crossref37. Deodhar, A, Conaghan, PG, Kvien, TK, et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol 2019; 37: 260–269.
Google Scholar | Medline38. Marzo-Ortega, H, Miceli-Richard, C, Gill, S, et al. Subcutaneous secukinumab 150 mg provides sustained relief in total and nocturnal back pain, morning stiffness, fatigue, and low disease activity in patients with active ankylosing spondylitis: end-of-study (5-year) data from the MEASURE 2 trial (Abstract 0364). Arthritis Rheumatol 2020; 72, https://acrabstracts.org/abstract/subcutaneous-secukinumab-150-mg-provides-sustained-relief-in-total-and-nocturnal-back-pain-morning-stiffness-fatigue-and-low-disease-activity-in-patients-with-active-ankylosing-spondylitis-end-of/
Google Scholar39. Marzo-Ortega, H, Miceli-Richard, C, Gill, S, et al. Subcutaneous secukinumab 150 mg provides rapid and sustained relief in total and nocturnal back pains, morning stiffness, and fatigue in patients with active ankylosing spondylitis over 4 years (Abstract 1504). Arthritis Rheumatol 2019; 71, https://acrabstracts.org/abstract/subcutaneous-secukinumab-150-mg-provides-rapid-and-sustained-relief-in-total-and-nocturnal-back-pains-morning-stiffness-and-fatigue-in-patients-with-active-ankylosing-spondylitis-over-4-years/
Google Scholar40. Marzo-Ortega, H, Deodhar, A, Blanco, R, et al. Secukinumab improves pain, morning stiffness, fatigue and physical function in tumor necrosis factor inhibitor-naïve patients with non-radiographic axial spondyloarthritis: results from a randomized controlled phase III study (Abstract 1340). Arthritis Rheumatol 2020; 72(Suppl. 10), https://acrabstracts.org/abstract/secukinumab-improves-pain-morning-stiffness-fatigue-and-physical-function-in-tumor-necrosis-factor-inhibitor-naive-patients-with-non-radiographic-axial-spondyloarthritis-results-from-a-randomized-c/
Google Scholar41. Poddubnyy, D, Pournara, E, Zielińska, A, et al. AB0659 secukinumab provides significant improvement of spinal pain in patients with axial spondyloarthritis: results from the 24-week phase 3 SKIPPAIN study. Ann Rheum Dis 2020; 79: 1624–1625.
Google Scholar | Crossref42. Kvien, TK, Conaghan, PG, Gossec, L, et al. Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis: long-term results of two phase III randomized controlled trials. Arthritis Care Res. Epub ahead of print 23 November 2020. DOI: 10.1002/acr.24517.
Google Scholar | Crossref43. Andreasen, RA, Kristensen, LE, Baraliakos, X, et al. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. Arthritis Res Ther 2020; 22: 177.
Google Scholar | Crossref | Medline44. Garrido-Cumbrera, M, Poddubnyy, D, Gossec, L, et al. The European map of axial spondyloarthritis: capturing the patient perspective-an analysis of 2846 patients across 13 countries. Curr Rheumatol Rep 2019; 21: 19.
Google Scholar | Crossref | Medline45. Deodhar, A, Gensler, LS, Magrey, M, et al. Assessing physical activity and sleep in axial spondyloarthritis: measuring the gap. Rheumatol Ther 2019; 6: 487–501.
Google Scholar | Crossref | Medline46. Zochling, J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res 2011; 63(Suppl. 11): S47–S58.
Google Scholar | Crossref | Medline | ISI47. Baraliakos, X, Van den Bosch, F, Machado, PM, et al. Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheumatol Ther 2021; 8: 273–288.
Google Scholar | Crossref | Medline48. Pavelka, K, Kivitz, AJ, Dokoupilova, E, et al. Secukinumab 150/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study. ACR Open Rheumatol 2020; 2: 119–127.